Biocept

Biocept Documents

Documents

3

Ticker

BIOCQ

ISIN

US09072V6002

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Biocept SEC Filings

Type
Report
Date
25-NSE25-NSE-Formular11/20/2023
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/22/2023
10-QQuartalsbericht8/14/2023

Biocept Documents 2026

This page contains all official documents and SEC filings for Biocept stock (BIOCQ, ISIN: US09072V6002). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 3 documents are available. Data is updated regularly to provide investors with a complete overview of Biocept's regulatory filings.

Biocept Stock analysis

Biocept Biocept, Inc. generates revenue through its oncology laboratory services, focusing on the detection of rare cells such as circulating tumor cells. The company markets its CNSide brand, which includes a suite of cellular and molecular technologies for central nervous system disease management. Its diagnostic assays, such as cell capture and enumeration, immunocytochemistry, FISH, and NGS, are commercialized for detecting various carcinomas and melanoma in blood and cerebrospinal fluid. Medical professionals and healthcare providers purchase these services to aid in patient diagnosis and treatment management. The CNSide product suite is designed for use in cerebrospinal fluid analysis, targeting solid tumor patients. Biocept's assays are specifically tailored for identifying rare tumor cells and cell-free tumor DNA, supporting clinical decision-making. The company's focus on solid tumors and CNS disease management positions it within the diagnostic laboratory services market, where healthcare institutions seek advanced tools for oncology care. Biocept's commercialized assays include cell capture, enumeration, immunocytochemistry, FISH, and NGS, all under the CNSide brand. These products are sold to medical professionals who require precise diagnostic tools for central nervous system disease management. The company's offerings are targeted at healthcare providers managing patients with solid tumors, particularly those requiring CSF analysis for disease monitoring and treatment planning.